Look back at news to Jan 27

29 January 2017
mergers-acquisitions-big

By Barbara Obstoj-Cardwell. Editor

Johnson & Johnson has agreed to pay $30 billion in cash for Actelion, and will not even get the whole drugs pipeline. Actelion shareholders should bite J&J’s arm off, according to the Financial Times’ Lex column.

This deal has the untidy look that can result from late concessions by an overly eager bidder when a rival acquirer is hovering. Founder and chief executive officer Jean-Paul Clozel will sail off into the sunset across Lake Lucerne helming a biotech comprising Actelion’s prospective and early stage treatments

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical